bladder%20cancer
BLADDER CANCER

Bladder cancer is a heterogenous neoplasm that ranges from non-life-threatening, low-grade, superficial papillary lesions to high-grade invasive tumors that often metastasizes at the presentation.

It is the most common cancer involving the urinary system and it is the 11th most commonly diagnosed in the world.

Microscopic or gross painless hematuria is the most common presenting complaint.

Introduction

  • Bladder cancer is an uncontrollable growth of cancer cells in the hollow organs of the pelvis which is the bladder
  • Most common cancer involving the urinary system & it is the 11th most commonly diagnosed in the world
    • It is the 6th common cancer in US & 7th in UK
    • It is the 10th most common cancer in men in Singapore
  • The predominant histologic type of bladder cancer is the urothelial (transitional cell) carcinoma
  • It is 3-4 times prevalent in men than in women
    • But women present w/ more advanced disease & have worse survival

Signs and Symptoms

Symptoms

  • Microscopic or gross painless hematuria is the most common presenting complaint
  • Urinary frequency from irritation or a reduced bladder capacity can also develop
  • Dysuria & urgency are other complaints
  • Less commonly, a urinary tract infection is the presenting symptom
  • Upper tract obstruction or pain may occur in more advanced tumors

Risk Factors

Risk factors

  • Active & passive tobacco smoking is the most important risk factor for bladder cancer
    • Tobacco smoke contains aromatic amines & polycyclic aromatic hydrocarbons that are renally excreted
  • Occupational exposure to aromatic amines, polycyclic aromatic hydrocarbons & chlorinated hydrocarbons is the second most important risk factor for bladder cancer
    • Occurs mainly in industrial plants processing paint, dye, metal & petroleum products
  • Increasing age
    • Mean age of diagnosis is 65 yrs
  • Exposure to ionizing radiation is connected w/ increased risk
    • There is an increased risk of developing bladder cancer in patients undergoing external-beam radiotherapy, brachytherapy or a combination
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Dr Joslyn Ngu, 23 Nov 2017
Highlights from the Joint Cancer Genetics Meeting and the 15th International Meeting on the Psychosocial Aspects of Hereditary Cancer (IMPAHC) 2017